
Introduction Childhood cancer treatment often involves chemotherapy, which is associated with adverse drug reactions/side effects that require close monitoring. Parents and guardians play a critical role in identifying and managing these reactions in children. This study assessed the awareness, attitudes, and proactive monitoring practices of parents/guardians regarding chemotherapy-related adverse drug reactions among children with cancer at a tertiary referral hospital in Tanzania. Methods A descriptive cross-sectional study was conducted among 200 parents/guardians of paediatric cancer patients receiving chemotherapy at Bugando Medical Centre, Mwanza, Tanzania. Data were collected using a semi-structured questionnaire and analysed using Stata version 16. Descriptive statistics, chi-square tests, and logistic regression analyses were performed. Results Most participants demonstrated low awareness of chemotherapy-related adverse drug reactions (80.5%). However, positive attitudes (58.5%) and proactive monitoring practices (69.0%) were observed. Female caregivers were more likely to demonstrate proactive monitoring practices than male caregivers (AOR = 1.97, 95% CI: 1.05–3.68, p = 0.03). Participants who were aware of chemotherapy-related adverse drug reactions were also more likely to demonstrate proactive monitoring practices (AOR = 3.19, 95% CI: 1.22–8.35, p = 0.02). Conclusions Despite limited awareness, parents and guardians demonstrated positive attitudes and self-reported proactive monitoring of their children for chemotherapy-related adverse drug reactions. Strengthening caregiver education and communication during cancer treatment may improve awareness, facilitate early recognition, reporting and appropriate management of adverse reactions. Clinical trial Number NA.
Introduction Prolonged infusion chair time negatively affects patient experience and limits operational capacity in outpatient oncology infusion settings. Advanced preparation and batching strategies reduce delays; however, the benefit of decentralized medication access has not been characterized. This study evaluated the impact of an anticipatory preparation strategy, scheduled batch preparation of pembrolizumab based on anticipated patient census data, with and without ADC point-of-care dispensing. Methods This single center, retrospective, pre-post study evaluated adult patients receiving pembrolizumab 200 mg monotherapy across three phases of operational changes: just-in-time compounding, after implementation of anticipatory preparation, and after anticipatory preparation plus ADC stocking in the infusion suite. The primary outcome was mean change in time from patient rooming to checkout. A secondary outcome was mean change in time from final product verification to medication administration. Outcomes were summarized using descriptive statistics and compared using one-way analysis of variance with Tukey's honestly significant difference tests. Results A total of 397 infusion encounters were analyzed. Mean rooming to checkout time decreased from 145.3 min at baseline to 140.4 min with anticipatory preparation and to 115.6 min following ADC stocking ( P = 0.0002). Mean dispense-to-administration time decreased from 19.5 min at baseline to 17.6 min with anticipatory preparation and to 6.7 min after ADC implementation (P < 0.001). Conclusions Anticipatory preparation of pembrolizumab was associated with modest reductions in medication administration time, while the addition of ADC stocking resulted in increased reduction of chair time. This approach may provide a scalable framework for improving operational efficiency in outpatient oncology infusion centers.
Objective BRAF inhibitors have been integrated into the treatment of several malignancies targeting the BRAF V600E-variant. However, there is limited evidence of the use of BRAF inhibitors in pregnancy. Hence, the purpose of this systematic review is to synthesize published reports evaluating the risk-benefit of BRAF inhibitor exposure during pregnancy. Methods A systematic search was conducted of PubMed, Scopus, Embase, Web of Science, and CINAHL Ultimate for articles published between January 1, 1966 and June 15, 2026. Included studies were those that involved women with a cancer diagnosis who received a BRAF inhibitor while pregnant and had clinical findings of the fetus post-BRAF inhibitor treatment. Results In total, 422 records were screened, yielding 7 cases of BRAF-inhibitor exposure during pregnancy. All patients presented with melanoma and vemurafenib was given in all but one case that used dabrafenib. Age of the mothers ranged from 25–37 years old. BRAF-inhibitor exposure occurred during the second trimester in 5 cases and in 1 case during the third trimester. Gestational age at delivery ranged from 26–36 weeks. The mother was alive at presentation in 2 of the 5 reported cases. Fetal adverse events occurred in 4 of the 7 cases including paroxysmal supraventricular tachycardia, intrauterine growth restriction, heart malformations, and delayed cranial ossification. Conclusion In this systematic review, BRAF inhibitor therapy during the second or third trimester of pregnancy may be associated with viable outcomes but carry significant potential risks to the fetus. Clinicians should approach BRAF inhibitor use during pregnancy with individualized, multi-disciplinary discussions.